Myeloid Immune Cells CARrying a New Weapon Against Cancer

Area of Science:

• Immunology
• Cell Therapy
• Oncology

Background:

• Chimeric antigen receptor (CAR) T and NK cell therapies are effective for hematologic cancers.
• CAR therapies face challenges in solid tumors due to the tumor microenvironment.
• Novel immune cell candidates are needed for effective solid tumor treatment.

Purpose of the Study:

• To explore mononuclear phagocytes as a potential CAR-engineered cell type for solid tumor treatment.
• To discuss the advantages of mononuclear phagocytes in overcoming solid tumor barriers.
• To review current research on CAR-myeloid cells in solid tumor models.

Main Methods:

• Review of tumor microenvironment elements.
• Analysis of mononuclear phagocyte features and advantages.
• Discussion of existing studies on CAR-myeloid cells in preclinical solid tumor models.

Main Results:

• Mononuclear phagocytes possess intrinsic properties like migration and phagocytosis beneficial for solid tumors.
• These cells can activate adaptive immunity and release soluble factors.
• CAR-engineered myeloid cells show potential in preclinical solid tumor studies.

Conclusions:

• Mononuclear phagocytes represent a promising cell type for CAR-based solid tumor immunotherapy.
• Their unique characteristics offer advantages over traditional CAR T/NK cells for solid tumors.
• Further research into CAR-myeloid cell therapy is warranted for solid tumor treatment.